CLOV — Clover Health Investments, Corp.

Clover Health Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Membership Growth: Clover Health reported a 48% year-over-year increase in Medicare Advantage membership, reaching an average of 157,000 members.
• Revenue: Total revenue for Q2 was $743 million, a 56% increase year-over-year, contributing to a first-half total of $1.5 billion.
• Profitability: The company generated $28 million in GAAP net income and $41 million in adjusted EBITDA for the quarter. Year-to-date, GAAP net income totaled $55 million, with adjusted EBITDA at $81 million.
• Gross Profit: Consolidated gross profit for Q2 was $153 million, reflecting a 54% year-over-year growth.
• Cash Position: Clover ended the quarter with $443 million in cash and investments, operating with no debt.

2. Strategic Updates and Business Highlights:

• Clover Assistant, the company's AI-powered tool, continues to enhance clinical decision-making, leading to improved care and profitability.
• The company achieved a four-and-a-half-star rating for its Medicare Advantage plans, which is expected to provide more flexibility in product offerings and growth strategies.
• The focus remains on core markets (New Jersey and Georgia) where Clover believes it can effectively manage member engagement and long-term economics.
• Investments are being made to enhance Clover Assistant and expand Counterpart Health's capabilities.

3. Forward Guidance and Outlook:

• Clover has increased its full-year guidance, expecting average Medicare Advantage membership of 156,000 to 158,000 members, total revenue between $2.92 billion and $3 billion, and consolidated gross profit of $525 million to $555 million.
• While not providing formal guidance for 2027, the company expressed confidence in entering the year with a larger, more mature membership base and improved cohort economics.

4. Bad News, Challenges, or Points of Concern:

• The company is facing ongoing litigation related to the star rating recalculation, with CMS appealing the district court's decision. This introduces uncertainty regarding future ratings and potential impacts on revenue.
• Although membership growth is strong, there are concerns about the initial economic pressures from new members who are still in early stages of care under Clover Assistant.
• Increased investments in the fourth quarter are expected, which may affect profitability during that period.

5. Notable Q&A Insights:

• In response to questions about cohort management, it was noted that approximately 21% of the current membership is from the 2025 cohort, while 28% is from the 2026 cohort.
• The company is monitoring cost trends closely, with expectations that underlying trends will remain consistent with national peers.
• Clover is optimistic about maintaining its star ratings, having historically performed well on HEDIS metrics, and is actively investing in quality improvements to sustain these ratings.

Overall, Clover Health demonstrated strong financial performance in Q2 2026, with significant membership growth and profitability. The company is strategically positioned for future growth, although it faces challenges related to litigation and the economic maturation of new members.